Clinical Trial

LATE-ONSET POMPE DISEASE AND CEREBROVASCULAR MANIFESTATIONS

Completed
View on ClinicalTrials.gov →
Summary
Late-onset Pompe disease (LOPD) is an inherited metabolic disorder caused by deficiency of acid alpha-glucosidase (GAA). In addition to skeletal and respiratory muscle involvement, previous studies suggest that patients with LOPD may have an increased frequency of cerebrovascular and aortic vascular abnormalities, but available evidence is limited. This multicenter, non-interventional study aims to determine whether pathogenic GAA mutations are associated with severe cerebrovascular or aortic vascular malformations. The study will include patients with confirmed LOPD and patients with intracranial aneurysms or subarachnoid hemorrhage. Clinical, laboratory, genetic, and imaging data will be collected to evaluate the frequency and characteristics of vascular abnormalities in LOPD and to identify previously undiagnosed cases presenting with vascular disease.
Trial Details
NCT Number NCT07685314
Lead Sponsor Hospitales Universitarios Virgen del Rocío
Collaborators: Sanofi
Conditions Late-Onset Pompe Disease
Enrollment 477 participants
Start Date 2020-05-01
Primary Completion 2025-04-16 (estimated)
Study Completion 2025-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-06